Cargando…
Recent advances in systemic therapy: Advances in systemic therapy for HER2-positive metastatic breast cancer
Human epidermal growth factor receptor (HER)2 over-expression is associated with a shortened disease-free interval and poor survival. Although the addition of trastuzumab to chemotherapy in the first-line setting has improved response rates, progression-free survival, and overall survival, response...
| Autores principales: | , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2009
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2750101/ https://www.ncbi.nlm.nih.gov/pubmed/19664181 http://dx.doi.org/10.1186/bcr2324 |